Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Positive Interim Data from Phase IV Test of Simcere’s Endu

publication date: Sep 3, 2008

Simcere Pharma reported that interim results from a Phase IV trial of its patented anti-cancer drug Endu showed the drug displayed both safety and efficacy. The data were in line with Endu’s Phase III trial. An anti-angiogenesis drug, Endu is a modified version of recombinant human endostatin. It is approved for use in China against non-small cell lung cancer, administered as an adjunct to platinum-class chemotherapy. Simcere said the results showed that Endu has a synergistic effect in this patient population, though the trial did not include patients who received platinum-class chemotherapy by itself. More details...

Stock Symbol: (NYSE: SCR)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here